165 related articles for article (PubMed ID: 35326597)
1. Synergy of Venetoclax and 8-Chloro-Adenosine in AML: The Interplay of rRNA Inhibition and Fatty Acid Metabolism.
Hoang DH; Morales C; Rodriguez IR; Valerio M; Guo J; Chen MH; Wu X; Horne D; Gandhi V; Chen LS; Zhang B; Pullarkat V; Rosen ST; Marcucci G; Buettner R; Nguyen LXT
Cancers (Basel); 2022 Mar; 14(6):. PubMed ID: 35326597
[TBL] [Abstract][Full Text] [Related]
2. Targeting the metabolic vulnerability of acute myeloid leukemia blasts with a combination of venetoclax and 8-chloro-adenosine.
Buettner R; Nguyen LXT; Morales C; Chen MH; Wu X; Chen LS; Hoang DH; Hernandez Vargas S; Pullarkat V; Gandhi V; Marcucci G; Rosen ST
J Hematol Oncol; 2021 Apr; 14(1):70. PubMed ID: 33902674
[TBL] [Abstract][Full Text] [Related]
3. 8-chloro-adenosine activity in FLT3-ITD acute myeloid leukemia.
Buettner R; Nguyen LXT; Kumar B; Morales C; Liu C; Chen LS; Pemovska T; Synold TW; Palmer J; Thompson R; Li L; Hoang DH; Zhang B; Ghoda L; Kowolik C; Kontro M; Leitch C; Wennerberg K; Yu X; Chen CC; Horne D; Gandhi V; Pullarkat V; Marcucci G; Rosen ST
J Cell Physiol; 2019 Sep; 234(9):16295-16303. PubMed ID: 30770553
[TBL] [Abstract][Full Text] [Related]
4. Therapy-Resistant Acute Myeloid Leukemia Stem Cells Are Resensitized to Venetoclax + Azacitidine by Targeting Fatty Acid Desaturases 1 and 2.
Culp-Hill R; Stevens BM; Jones CL; Pei S; Dzieciatkowska M; Minhajuddin M; Jordan CT; D'Alessandro A
Metabolites; 2023 Mar; 13(4):. PubMed ID: 37110126
[TBL] [Abstract][Full Text] [Related]
5. 8-Cl-Ado and 8-NH
Guo J; Buettner R; Du L; Li Z; Liu W; Su R; Chen Z; Che Y; Zhang Y; Ma R; Nguyen LXT; Moore RE; Khyatiben P; Chen MH; Patrick P; Wu X; Marcucci G; Wang L; Horne D; Chen J; Yang Y; Rosen ST
Leukemia; 2024 Apr; ():. PubMed ID: 38643304
[TBL] [Abstract][Full Text] [Related]
6. Nicotinamide Metabolism Mediates Resistance to Venetoclax in Relapsed Acute Myeloid Leukemia Stem Cells.
Jones CL; Stevens BM; Pollyea DA; Culp-Hill R; Reisz JA; Nemkov T; Gehrke S; Gamboni F; Krug A; Winters A; Pei S; Gustafson A; Ye H; Inguva A; Amaya M; Minhajuddin M; Abbott D; Becker MW; DeGregori J; Smith CA; D'Alessandro A; Jordan CT
Cell Stem Cell; 2020 Nov; 27(5):748-764.e4. PubMed ID: 32822582
[TBL] [Abstract][Full Text] [Related]
7. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis in vitro.
Hurrish KH; Su Y; Patel S; Ramage CL; Zhao J; Temby BR; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Biochem Pharmacol; 2024 Feb; 220():115981. PubMed ID: 38081370
[TBL] [Abstract][Full Text] [Related]
8. Fatty acid metabolism underlies venetoclax resistance in acute myeloid leukemia stem cells.
Stevens BM; Jones CL; Pollyea DA; Culp-Hill R; D'Alessandro A; Winters A; Krug A; Abbott D; Goosman M; Pei S; Ye H; Gillen AE; Becker MW; Savona MR; Smith C; Jordan CT
Nat Cancer; 2020 Dec; 1(12):1176-1187. PubMed ID: 33884374
[TBL] [Abstract][Full Text] [Related]
9. Enhancing anti-AML activity of venetoclax by isoflavone ME-344 through suppression of OXPHOS and/or purine biosynthesis.
Hurrish KH; Su Y; Patel S; Ramage CL; Carter JL; Edwards H; Buck SA; Wiley SE; Hüttemann M; Polin L; Kushner J; Dzinic SH; White K; Bao X; Li J; Yang J; Boerner J; Hou Z; Al-Atrash G; Konoplev SN; Busquets J; Tiziani S; Matherly LH; Taub JW; Konopleva M; Ge Y; Baran N
Res Sq; 2023 Apr; ():. PubMed ID: 37162954
[TBL] [Abstract][Full Text] [Related]
10. A phase 1 trial of 8-chloro-adenosine in relapsed/refractory acute myeloid leukemia: An evaluation of safety and pharmacokinetics.
Pullarkat V; Chen LS; Palmer J; Zhang J; Synold TW; Buettner R; Truong Nguyen LX; Marcucci G; Tsai NC; Wang Y; O'Hearn J; Gandhi V; Rosen ST
Cancer; 2024 Mar; 130(5):727-739. PubMed ID: 37897709
[TBL] [Abstract][Full Text] [Related]
11. Oxidative Phosphorylation Fueled by Fatty Acid Oxidation Sensitizes Leukemic Stem Cells to Cold.
Griessinger E; Pereira-Martins D; Nebout M; Bosc C; Saland E; Boet E; Sahal A; Chiche J; Debayle D; Fleuriot L; Pruis M; De Mas V; Vergez F; Récher C; Huls G; Sarry JE; Schuringa JJ; Peyron JF
Cancer Res; 2023 Aug; 83(15):2461-2470. PubMed ID: 37272750
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous inhibition of Sirtuin 3 and cholesterol homeostasis targets acute myeloid leukemia stem cells by perturbing fatty acid β-oxidation and inducing lipotoxicity.
O'Brien C; Ling T; Berman JM; Culp-Hill R; Reisz JA; Rondeau V; Jahangiri S; St-Germain J; Macwan V; Astori A; Zeng A; Hong JY; Li M; Yang M; Jana S; Gamboni F; Tsao E; Liu W; Dick JE; Lin H; Melnick A; Tikhonova A; Arruda A; Minden MD; Raught B; D'Alessandro A; Jones CL
Haematologica; 2023 Sep; 108(9):2343-2357. PubMed ID: 37021547
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of topoisomerase II by 8-chloro-adenosine triphosphate induces DNA double-stranded breaks in 8-chloro-adenosine-exposed human myelocytic leukemia K562 cells.
Yang SY; Jia XZ; Feng LY; Li SY; An GS; Ni JH; Jia HT
Biochem Pharmacol; 2009 Feb; 77(3):433-43. PubMed ID: 19014910
[TBL] [Abstract][Full Text] [Related]
14. 8-Chloro-Adenosine Inhibits Proliferation of MDA-MB-231 and SK-BR-3 Breast Cancer Cells by Regulating ADAR1/p53 Signaling Pathway.
Ding HY; Yang WY; Zhang LH; Li L; Xie F; Li HY; Chen XY; Tu Z; Li Y; Chen Y; Yang SY
Cell Transplant; 2020; 29():963689720958656. PubMed ID: 32907379
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparison of salvage intensive chemotherapy
Park S; Kwag D; Kim TY; Lee JH; Lee JY; Min GJ; Park SS; Yahng SA; Jeon YW; Shin SH; Yoon JH; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Lee JW; Kim HJ
Ther Adv Hematol; 2022; 13():20406207221081637. PubMed ID: 35340720
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 study of the pan-bromodomain and extraterminal inhibitor mivebresib (ABBV-075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia.
Borthakur G; Odenike O; Aldoss I; Rizzieri DA; Prebet T; Chen C; Popovic R; Modi DA; Joshi RH; Wolff JE; Jonas BA
Cancer; 2021 Aug; 127(16):2943-2953. PubMed ID: 33934351
[TBL] [Abstract][Full Text] [Related]
17. 8-chloro-cAMP and 8-chloro-adenosine act by the same mechanism in multiple myeloma cells.
Gandhi V; Ayres M; Halgren RG; Krett NL; Newman RA; Rosen ST
Cancer Res; 2001 Jul; 61(14):5474-9. PubMed ID: 11454694
[TBL] [Abstract][Full Text] [Related]
18. Selinexor Synergistically Promotes the Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia by Inhibiting Glycolytic Function and Downregulating the Expression of DNA Replication Genes.
Jiang J; Wang Y; Liu D; Wang X; Zhu Y; Tong J; Chen E; Xue L; Zhao N; Liang T; Zheng C
Immunotargets Ther; 2023; 12():135-147. PubMed ID: 38026089
[TBL] [Abstract][Full Text] [Related]
19. Repressing HIF-1α-induced HDAC9 contributes to the synergistic effect of venetoclax and MENIN inhibitor in KMT2Ar AML.
Ling Q; Zhou Y; Qian Y; Qian J; Zhang Y; Wang J; Zhu Y; Zhou Y; Wei J; Yang C; Sun J; Yu W; Jin J; Zhang X
Biomark Res; 2023 Dec; 11(1):105. PubMed ID: 38053201
[TBL] [Abstract][Full Text] [Related]
20. Single-center pediatric experience with venetoclax and azacitidine as treatment for myelodysplastic syndrome and acute myeloid leukemia.
Winters AC; Maloney KW; Treece AL; Gore L; Franklin AK
Pediatr Blood Cancer; 2020 Oct; 67(10):e28398. PubMed ID: 32735397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
